103127-55-5

Upstream product

• 1048676-57-8 ethyl N-(diphenylmethylene)-DL-cyclohexylalaninate 
• 144186-13-0 N-tert-butoxycarbonyl-cyclohexylalanine 
• 856758-85-5 ethyl 2-amino-3-cyclohexylpropionate 
• 87413-09-0 Dess-Martin periodane 
• 194342-34-2 [(S)-2-cyclohexyl-1-(hydroxymethyl)ethyl]carbamic acid,1,1-dimethylethyl ester 

Downstream Products

• 115131-78-7 (2-cyano-1-cyclohexylmethyl-2-hydroxy-ethyl)-carbamic acid tert-butyl ester 
• 1124281-27-1 3-endo-[8-(2-amino-3-cyclohexylpropyl)-8-aza-bicyclo[3.2.1]oct-3-yl]phenol 
• 113785-85-6 (2-carbamoyl-1-cyclohexylmethyl-2-hydroxy-ethyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists

The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provid

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection

Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.

Method for the production of aldehydes

A process for the manufacture of aldehydes by the catalytic reduction of carboxylic acid halides with hydrogen in the presence of an alkylene oxide.

RENIN INHIBITING COMPOUNDS

Compounds which are amino acid derivatives and have the formula STR1 in which R 1 is hydrogen or methyl, R 2 is ethyl, propyl or imidazol-4-yl, R 3 is isobutyl, cyclohexylmethyl or benzyl, and A is defined as herein are useful as renin inhibitors.

N-HETEROCYCLIC ALCOHOL DERIVATIVES

Compounds of the formula STR1 wherein R 1 is an N-heterocyclic group as defined herein, are disclosed. These compounds are inhibitors of renin and therefore useful as cardiovascular agents.

AMINO ACID DERIVATIVES WHICH HAVE RENIN INHIBITING ACTIVITY

The compounds of the formula STR1 wherein A, R 1, R. sup.2, R. sup.3 and R 4 have the significance given in claim 1, in the form of optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates as well as pharmaceutically usable salts thereof inhibit the activity of the natural enzyme renin and can accordingly be used in the form of pharmaceutical preparations in the control or prevention of high blood pressure and cardiac insufficiency.

N-HETEROCYCLIC ALCOHOL DERIVATIVES

Compounds of the formula STR1 wherein R 1 is an N-heterocyclic group as defined herein and Y can be--NH--,--O--or--CH. sub.2--, are disclosed. These compounds are inhibitors of renin and therefore useful as cardiovascular agents.